Pathogenesis and classification of proliferative diabetic vitreoretinopathy

Ophthalmologica

Volumn 221, Issue 2, 2007, Pages 78-94

  Kroll, Peter ^a,b   Büchele Rodrigues, Eduardo ^a   Hoerle, Steffen ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Klinik fur Augenheilkunde   (Germany)

Author keywords

Diabetes; Neovascularization; Proliferative diabetic retinopathy; Proliferative diabetic vitreoretinopathy; Retina; Vascular endothelial growth factor

Indexed keywords

ANGIOSTATIN; GLUCOSE; HEMOGLOBIN A1C; VASCULOTROPIN;

ANGIOGENESIS; CILIARY DISK; COURSE EVALUATION; DIABETIC RETINOPATHY; DIABETIC VITREORETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LASER COAGULATION; METABOLIC REGULATION; PATHOGENESIS; PIGMENT EPITHELIUM; PREDICTION; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; REVIEW; RISK FACTOR; SCREENING TEST; UPREGULATION; VITRECTOMY; VITREOUS BODY; WAIST HIP RATIO;

DIABETIC RETINOPATHY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RISK FACTORS; VITREORETINOPATHY, PROLIFERATIVE;

EID: 33947504474     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098253     Document Type: Review

References (123)

1. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
3. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
4. Aiello LP: Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-135.
5. Aiello LP: The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47:S263-S269.
6. Akiba J, Ueno N, Chakrabarti B: Molecular mechanisms of posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 1993;231:408-412.
7. Arden GB: The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Ophthalmol 2001;85:366-370.
8. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F: Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy, and macular pucker. Ophthalmologica 1998;212:410-414.
9. Augustin AJ, Keller A, Koch F, Jurklies B, Dick B: Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy. Klin Monatsbl Augenheilkd 2001;218:89-94.
10. Barber AJ, Antonetti DA, Gardner TW: Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000;41:3561-3568.
11. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW: Neural apoptosis in the retina during experimental and human diabetes:early onset and effect of insulin. J Clin Invest 1998;102:783-791.
12. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 2000;41:1153-1158.
13. Bodanowitz S, Hesse L, Weinand F, Kroll P: Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand 1996;74:84-88.
14. Boeri D, Maiello M, Lorenzi M: Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001;50:1432-1439.
15. Cai J, Boulton M: The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002;16:242-260.
16. Canton A, Burgos R, Hernandez C, Mateo C, Segura RM, Mesa J, Simo R: Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Br J Ophthalmol 2000;84:732-735.
17. Casaroli Marano RP, Preissner KT, Vilaro S: Fibronectin, laminin, vitronectin and their receptors at newly formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 1995;60:5-17.
18. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S: Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 2000;16:393-407.
19. Chantelau E, Kohner EM, Seppel T, Schonau E, Althaus C: Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome. Br J Ophthalmol 1997;81:169-170.
20. Chantelau E: Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998;82:725-730.
21. Chantelau E: Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy. Ophthalmology 2002;109:2187.
22. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
23. Chiarelli F, Santilli F, Mohn A: Role of growth factors in the development of diabetic complications. Horm Res 2000;53:53-67.
24. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC-beta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-179.
25. Davis MD, Norton EWD, Myers FL: The Airlie classification of diabetic retinopathy; in Goldberg MF, Fine SL (eds): Symposium on the Treatment of Diabetic Retinopathy, Washington, US Government Printing Office, 1969, pp. 7-22. USPHS pub No 1890.
26. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-248.
27. Dawson VL, Dawson TM: Nitric oxide in neurodegeneration. Prog Brain Res 1998;118:215-229.
28. Diabetes Control and Complications Trial Study Group: The absence of a glycemic threshold for the development of long-term complications:the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
29. A modification of the Airlie House classification of diabetic retinopathy. Diabetic Retinopathy Study report No 7. Invest Ophthalmol Vis Sci 1981;21:210-226.
30. Diabetic Retinopathy Vitrectomy Study Research Group: Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985;103:1644-1652.
31. Dwyer MS, Melton LJ 3rd, Ballard DJ, Palumbo PJ, Trautmann JC, Chu CP: Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 1985;8:316-322.
32. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report No 10. Ophthalmology 1991;98:786-806.
33. Emmerich KH, Kroll P, Berlage F: Fluorescein angiographic long-term controls in patients with proliferative diabetic retinopathy and vitrectomy. Fortschr Ophthalmol 1986;83:474-476.
34. Faulborn J, Bowald S: Microproliferations in proliferative diabetic retinopathy and their relationship to the vitreous: corresponding light and electron microscopic studies. Graefes Arch Clin Exp Ophthalmol 1985;223:130-138.
35. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543.
36. Fong DS: Changing times for the management of diabetic retinopathy. Surv Ophthalmol 2002;47:S238-S245.
37. Foos RY, Wheeler NC: Vitreoretinal juncture: synchysis senilis and posterior vitreous detachment. Ophthalmology 1982;89:1502-1512.
38. Foos RY: Vitreoretinal juncture; epiretinal membranes and vitreous. Invest Ophthalmol Vis Sci 1977;16:416-422.
39. Frank RN: Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002;133:693-698.
40. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47:S253-S262.
41. Goldfarb S, Ziyadeh FN, Kern EF, Simmons DA: Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991;40:465-471.
42. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108:2266-2272.
43. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED: Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999;42:728-736.
44. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G: Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401-406.
45. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002;51:3107-3112.
46. Hammes HP, Wellensiek B, Kloting I, Sickel E, Bretzel RG, Brownlee M: The relationship of glycemic level to advanced glycation endproduct (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998;41:165-170.
47. Hata Y, Clermont A, Yamauchi T, Pierce EA, Suzuma I, Kagokawa H, Yoshikawa H, Robinson GS, Ishibashi T, Hashimoto T, Umeda F, Bursell SE, Aiello LP: Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J Clin Invest 2000;106:541-550.
48. Hendrikse F, Yeo KT: Role of the vitreous body in diabetic retinopathy. Klin Monatsbl Augenheilkd 1993;203:319-323.
49. Hernandez C, Lecube A, Segura RM, Sararols L, Simo R: Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2002;19:655-660.
50. Hesse L, Bodanowitz S, Hühnermann M, Kroll P: Prediction of visual acuity after early vitrectomy in diabetics. Ger J Ophthalmol 1996;5:257-261.
51. Hesse L, Heller G, Kraushaar N, Wesp A, Schroeder B, Kroll P: The predictive value of a classification for proliferative diabetic vitreoretinopathy. Klin Monatsbl Augenheilkd 2002;219:46-49.
52. Hesse L, Kroll P: Enzymatically induced posterior vitreous detachment in proliferative diabetic vitreoretinopathy. Klin Monatsbl Augenheilkd 1999;214:84-89.
53. Hesse L, Kroll P: TPA-assisted vitrectomy for proliferative diabetic retinopathy. Retina 2000;20:317-318.
54. Hesse L, Kroll P: What is the ophthalmologic recommendation for managing diabetes with reference to diabetic retinopathy. Internist (Berl) 1993;34:477.
55. Hoerle S, Gruner F, Kroll P: Epidemiology of diabetes-induced blindness - a review. Klin Monatsbl Augenheilkd 2002;219:777-784.
56. Hoerle S, Poestgens H, Schmidt J, Kroll P: Effect of pars plana vitrectomy for proliferative diabetic vitreoretinopathy on preexisting diabetic maculopathy. Graefes Arch Clin Exp Ophthalmol 2002;240:197-201.
57. Hovener G: The influence of refraction on diabetic retinopathy. Klin Monatsbl Augenheilkd 1975;167:733-736.
58. Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E: Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1649-1656.
59. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular disfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731.
60. Joussen AM, Fauser S, Krohne TU, Lemmen KD, Lang GE, Kirchhof B: Diabetic retinopathy: pathophysiology and therapy of hypoxia-induced inflammation. Ophthalmologe 2003;100:363-370.
61. Joussen AM, Kirchhof B, Gottstein C: Molecular mechanisms of vasculogenesis and angiogenesis: what regulates vascular growth? Ophthalmologe 2003;100:284-291.
62. Joussen AM: Angiogenesis in ophthalmology. 2. Current considerations on the pathogenesis of diabetic and hypoxia-induced retinopathy. Ophthalmologe 2003;100:361-362.
63. Kador PF, Takahashi Y, Wyman M, Ferris F 3rd: Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1995;113:352-354.
64. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
65. Kerty E, Russell D, Bakke SJ, Nyberg-Hansen R, Rootwell K: Regional cerebral blood flow (rCBF) and cerebral vasoreactivity in patients with retinal ischaemic symptoms. J Neurol Neurosurg Psychiatry 1989;52:1345-1350.
66. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 1998;105:1801-1815.
67. Klein R, Klein BE, Moss SE: Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992;15:1875-1891.
68. Klein R: Has the frequency of proliferative diabetic retinopathy declined in the US. Diabetes Care 2003;26:2691-2692.
69. Klein R: Prevention of visual loss from diabetic retinopathy. Surv Ophthalmol 2002;47:S246-S252.
70. Kohno T, Sorgente N, Goodnight R, Ryan SJ: Alterations in the distribution of fibronectin and laminin in the diabetic human eye. Invest Ophthalmol Vis Sci 1987;28:515-521.
71. Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ: Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987;28:506-514.
72. Kroll P, Meyer-Rusenberg HW, Berg P: Does vitrectomy in case of proliferative diabetic retinopathy lead to a better intraocular metabolism? Fortschr Ophthalmol 1986;83:471-473.
73. Kroll P, Meyer-Rusenberg HW, Busse H: Recommendation for staging of proliferative diabetic retinopathy. Fortschr Ophthalmol 1987;84:360-363.
74. Kroll P, Wiegand W, Schmidt J: Vitreopapillary traction in proliferative diabetic vitreoretinopathy. Br J Ophthalmol 1999;83:261-264.
75. Krumpaszky HG, Klauss V: Epidemiology of blindness and eye disease. Ophthalmologica 1996;210:1-86.
76. Lakshminarayanan S, Antonetti DA, Gardner TW, Tarbell JM: Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO. Invest Ophthalmol Vis Sci 2000;41:4256-4261.
77. Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH: Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1999;40:2453-2457.
78. Lonneville YH, Ozdek SC, Onol M, Yetkin I, Gurelik G, Hasanreisoglu B: The effect of blood glucose regulation on retinal nerve fiber layer thickness in diabetic patients. Ophthalmologica 2003;217:347-350.
79. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-1482.
80. Matsugi T, Chen Q, Anderson DR: Contractile responses of cultured bovine retinal pericytes to angiotensin II. Arch Ophthalmol 1997;115:1281-1285.
81. Merimee TJ: Diabetic retinopathy:a synthesis of perspectives. N Engl J Med 1990;322:978-983.
82. Mitamura Y, Takeuchi S, Ohtsuka K, Matsuda A, Yamamoto T, Yamamoto S, Hiraiwa N, Kusakabe M: Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy. Ophthalmologica 2003;217:422-425.
83. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997;40:764-769.
84. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
85. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997;151:281-291.
86. Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T: Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina 2001;21:647-651.
87. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-3139.
88. Porta M, Bandello F: Diabetic retinopathy:a clinical update. Diabetologia 2002;45:1617-1634.
89. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, Fuller JH; EURODIAB Prospective Complications Study Group: Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001;44:2203-2209.
90. Poulsen JE: The Houssay phenomenon in man:recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 1953;2:7-12.
91. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1971-1980.
92. Rymaszewski Z, Cohen RM, Chomczynski P: Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA:1991;88:617-621.
93. Sato Y, Lee Z: The subclassification and long-term prognosis of preproliferative diabetic retinopathy. Jpn J Ophthalmol 2002;46:323-329.
94. Schalekamp MADH: Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease. Clin Invest 1993;71:S3-S6.
95. Schulze S, Schulze S, Schmidt J, Kroll P: Air endotamponade in 52 vitrectomies due to proliferative diabetic retinopathy - retrospective comparison with 40 vitrectomies without endotamponade. Klin Monatsbl Augenheilkd 2000;217:329-333.
96. Sebag J, Buckingham B, Charles MA, Reiser K: Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992;110:1472-1476.
97. Sebag J, Buzney SM, Belyea DA, Kado M, McMeel JW, Trempe CL: Posterior vitreous detachment following panretinal laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 1990;228:5-8.
98. Sebag J, Hageman GS: Interfaces. Rome, Fondazione GB Bietti, 2000, chap IV, pp 62-65.
99. Sebag J: The Vitreous - Structure, Function and Pathobiology. New York, Springer, 1989, pp 106-107.
100. Sebag J: Diabetic vitreopathy. Ophthalmology 1996;103:205-206.
101. Shea M: Early vitrectomy in proliferative diabetic retinopathy. Arch Ophthalmol 1983;101:1204-1205.
102. Simo R, Lecube A, Segura RM, Garcia Arumi J, Hernandez C: Free insulin-like growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 2002;134:376-382.
103. Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller J: Retinopathy and vision loss in insulin-dependent diabetes in Europe. Ophthalmology 1997;104:252-260.
104. Smith JA, Davis CL, Burgess GM: Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. Eur J Neurosci 2000;12:3250-3258.
105. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-1395.
106. Sozmen EY, Sozmen B, Delen Y, Onat T: Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res 2001;32:283-287.
107. Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF: Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy:association with retinal photocoagulation. Diabetologia 2000;43:1404-1407.
108. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 1995;92:11-14.
109. +- ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994;94:853-859.
110. Stitt AW, Gardiner TA, Archer DB: Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 1995;79:362-367.
111. Stitt AW: Advanced glycation:an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001;85:746-753.
112. Stitt AW: The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003;75:95-108.
113. Takahashi T, Hato F, Yamane T, Fukumasu H, Suzuki K, Ogita S, Nishizawa Y, Kitagawa S: Activation of human neutrophil by cytokine-activated endothelial cells. Circ Res 2001;88:422-429.
114. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
115. Tsai DC, Chiou SH, Lee FL, Chou CK, Chen SJ, Peng CH, Kuo YH, Chen CF, Ho LL, Hsu WM: Possible involvement of nitric oxide in the progression of diabetic retinopathy. Ophthalmologica 2003;217:342-346.
116. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
117. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
118. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z: Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 1991;16:268-271.
119. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT; Global Diabetic Retinopathy Project Group: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677-1682.
120. Wilkinson-Berka JL, Kelly DJ, Gilbert RE: The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vasc Res 2001;38:527-535.
121. Williams B, Gallacher B, Patel H, Orme C: Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-1503.
122. Yu DY, Cringle SJ, Alder VA: The response of rat vitreal oxygen tension to stepwise increases in inspired percentage oxygen. Invest Ophthalmol Vis Sci 1990;31:2493-2499.
123. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.